Anti-Human CD49D (Integrin alpha 4) (Natalizumab)
| Code | Size | Price |
|---|
| LEI-LT1100-Custom | Custom | Enquire |
Quantity:
| LEI-LT1100-1mg | 1.0 mg | £207.00 |
Quantity:
| LEI-LT1100-5mg | 5.0 mg | £532.00 |
Quantity:
| LEI-LT1100-25mg | 25 mg | £1,677.00 |
Quantity:
| LEI-LT1100-50mg | 50 mg | £2,902.00 |
Quantity:
| LEI-LT1100-100mg | 100 mg | £4,066.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: Hu114
Regulatory Status: RUO
Target Species: Human
Applications:
- Blocking
- Flow Cytometry
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.
Further Information
Antigen Distribution:
CD49D is a subunit of the integrin VLA-4, which is expressed on the cell surfaces of stem cells, progenitor cells, T and B cells, monocytes, natural killer cells, eosinophils, and neutrophils.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
RAMOS cell line injected into mice.
Long Description:
Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)), and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and α4β1-integrin interaction is necessary for leukocyte adhesion, firm attachment, and transmigration across the blood-brain barrier into the CNS. Natalizumab, a recombinant, humanized antibody, binds to α4β1 -integrin and blocks its interaction with VCAM-1. Hence, leukocyte migration into brain tissue is inhibited, thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking α4β7-integrin with a humanized, monoclonal antibody, specific to the α4β7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue, thus, reducing inflammation in the gut.2 This cost-effective, research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects.
NCBI Gene:
3676
Purity:
?95% monomer by analytical SEC
Target:
CD49D
References
1. Hutchinson, M. (2007) Ther Clin Risk Manag. 3(2):259-68.
2. Vandervoort, M. et al. (2005) N Engl J Med 352:2499-507.